Albany, NY -- (SBWire) -- 11/15/2018 --A recent report by ResearchMoz.us, titled, "Stem Cell Therapies in Neurology," discusses the prospects of the new treatment. To that end, it tries to study the various stakeholders in the business and the various methods and technologies being leveraged by them.

The report states at the outset that stem cell therapies in neurology is an upcoming field that has a lot of potential. There is already a lot of excitement about the possibility of leveraging stem cells to tackle incurable diseases of the brain, even if they are late onset neurodegenerative disorders such as Parkinson's disease (PD) or early stage inflammatory diseases such as multiple sclerosis.

At present, the pipeline of products consist of various types of stem cells and the therapies can be useful for a wide gamut of neurological disorders.

Get a Sample PDF: https://www.researchmoz.us/enquiry.php?type=S&repid=1918214

Despite, appearing so promising, stem cell therapies in neurology are nevertheless running into headwinds. Those include the complicated nature of developing the therapies alongside the need to ensure the safety and efficacy of the data. For example, the process to replenish the neural cells that are already lost with diseases progress, is an involved one. It includes the need to ensure that the stem cells can be an authentic replacement of the neurons in question, the need to demonstrate their reproducibility in the laboratory, and testing those in animal models to check their long-term benefits.

At present, biotechnology companies are currently playing a pioneering role in stem cell therapies in neurology. They are predicted to lead the development of a range of pipeline products. At present, the pipeline is comprised of 16 products, spanning all the three phases – first, second, and third. The indications for which these products are being evaluated include Parkinson's disease, Alzheimer's disease, and Amyotrophic Lateral Sclerosis (ALS).

The report states that at present most of the research in stem cell therapies in neurology is directed at efficacy, safety, and mechanism of action underpinning the cell therapy. Substantial investment is also being made in new and improved technologies that can improve the functional outcomes.

Apart from that, the report also details the regulatory agencies and procedures pertaining to stem cell therapies in neurology. It particularly focuses on the U.S., Germany, France, Spain, Italy, China, the U.K., and Japan.

The report presents detailed information on the ongoing clinical trials and challenges in the domain of stem cells in neurology. It throws light on the unmet needs in the domain and what progress has been made so far. To that end, it interviews key opinion leaders in the space who try and elaborate if the pipeline products would be able to satisfy the current unmet needs. They also try and explain the most promising candidates in late stage clinical trials.

Contact Us:
Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG